Harvard Bioscience (HBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -669 | -7,810 | -7,195 | -6,097 | -4,516 |
| Depreciation Amortization | 1,979 | 8,812 | 6,006 | 4,060 | 2,009 |
| Income taxes - deferred | -53 | -23 | 29 | 423 | N/A |
| Accounts receivable | 584 | 3,105 | 6,805 | 5,855 | 5,149 |
| Accounts payable and accrued liabilities | -245 | 1,491 | 586 | 1,925 | 2,739 |
| Other Working Capital | -1,188 | 4,106 | 5,360 | 5,296 | 4,747 |
| Other Operating Activity | 629 | -350 | -4,750 | -6,218 | -7,257 |
| Operating Cash Flow | $1,037 | $9,331 | $6,841 | $5,244 | $2,871 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -151 | -1,152 | -1,088 | -524 | -241 |
| Purchase Sale Intangibles | -150 | -250 | N/A | N/A | N/A |
| Other Investing Activity | -150 | -250 | 0 | 0 | 0 |
| Investing Cash Flow | $-301 | $-1,402 | $-1,088 | $-524 | $-241 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 61,315 | 9,615 | 6,115 | N/A |
| Debt Repayment | -500 | -66,912 | -20,251 | -16,411 | -4,829 |
| Common Stock Issued | 1,924 | 669 | 194 | 187 | -242 |
| Other Financing Activity | -4,565 | -3,039 | -882 | -262 | 0 |
| Financing Cash Flow | $-3,141 | $-7,967 | $-11,324 | $-10,371 | $-5,071 |
| Exchange Rate Effect | -97 | 20 | 42 | -55 | -12 |
| Beginning Cash Position | 8,317 | 8,335 | 8,335 | 8,335 | 8,335 |
| End Cash Position | 5,815 | 8,317 | 2,806 | 2,629 | 5,882 |
| Net Cash Flow | $-2,502 | $-18 | $-5,529 | $-5,706 | $-2,453 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,037 | 9,331 | 6,841 | 5,244 | 2,871 |
| Capital Expenditure | -151 | -1,152 | -1,088 | -524 | -241 |
| Free Cash Flow | 886 | 8,179 | 5,753 | 4,720 | 2,630 |